{"id":2401,"date":"2018-11-14T17:57:00","date_gmt":"2018-11-14T17:57:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2401"},"modified":"2025-01-15T02:58:26","modified_gmt":"2025-01-15T02:58:26","slug":"australia-on-track-to-achieve-who-hcv-elimination-targets-following-rapid-initial-daa-treatment-uptake-a-modeling-study","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/australia-on-track-to-achieve-who-hcv-elimination-targets-following-rapid-initial-daa-treatment-uptake-a-modeling-study\/","title":{"rendered":"Australia en camino de alcanzar los objetivos de eliminaci\u00f3n del VHC de la OMS tras la r\u00e1pida adopci\u00f3n inicial del tratamiento con AAD: un estudio de modelo"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<p>El tratamiento antiv\u00edrico de acci\u00f3n directa subsidiado (DAA) recientemente estuvo disponible para todos los adultos que viven con hepatitis C cr\u00f3nica (VHC) en Australia. Bas\u00e1ndonos en la r\u00e1pida asimilaci\u00f3n (32,600 personas iniciaron DAA en 2016), estimamos el impacto en la epidemiolog\u00eda y la mortalidad del VHC en Australia y determinamos si Australia puede cumplir con los objetivos de eliminaci\u00f3n del VHC de la OMS para 2030. Utilizando un modelo matem\u00e1tico, simulamos pesimistas, intermedios y optimistas. Escenarios de tratamiento de AAD en Australia durante 2016-2030. Supusimos que las tasas de tratamiento y pruebas eran inicialmente m\u00e1s altas para la fibrosis avanzada y las mismas en todas las subpoblaciones de niveles de riesgo de transmisi\u00f3n del VHC. Tambi\u00e9n asumimos tasas de prueba constantes despu\u00e9s de 2016. Comparamos los resultados con el nivel de 2015 y un escenario hipot\u00e9tico (basado en IFN). Durante 2016-2030, estimamos un escenario de tratamiento intermedio de AAD (2016, 32,600 tratados; 2017, 21,370 tratados; 2018,17,100 tratados; 2019 y m\u00e1s all\u00e1, 13,680 tratados cada a\u00f1o) evitar\u00eda 40,420 nuevas infecciones por VHC, 13,260 muertes relacionadas con el h\u00edgado ( 15,320 en vir\u00e9micos; -2,060 en curados) y 10,730 casos de HCC, lo que equivale a una reducci\u00f3n de 53%, 63% y 75% respectivamente, en comparaci\u00f3n con el escenario basado en IFN. El modelo tambi\u00e9n estim\u00f3 que Australia cumplir\u00e1 con los objetivos de incidencia y tratamiento de la OMS para 2028. El tiempo hasta una reducci\u00f3n de 65% en la mortalidad relacionada con el h\u00edgado vari\u00f3 considerablemente entre los casos de virus de hepatitis C (2026) y todos los casos (2047). Sobre la base de un escenario de tratamiento factible de AAD que incorpore la disminuci\u00f3n de la absorci\u00f3n, Australia deber\u00eda cumplir los objetivos clave de eliminaci\u00f3n del VHC de la OMS en 10 a 15 a\u00f1os. La escalada previa a la AAD en personas con enfermedad hep\u00e1tica avanzada dificulta el logro del objetivo de mortalidad relacionada con el h\u00edgado.<\/p>\n\n\n\n<p><strong>Pa\u00edses:<\/strong> Australia<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30267593\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Subsidized direct-acting antiviral (DAA) treatment recently became available to all adults living with chronic hepatitis C (HCV) in Australia. Based on rapid uptake (32,600 people initiated DAA in 2016) we estimated the impact on HCV epidemiology and mortality in Australia and determined if Australia can meet the WHO HCV elimination targets by 2030. Using [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3193,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10,12],"publication-author":[767,768,535,771,706,766,769,772,704,770,494],"class_list":["post-2401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","tag-modelling","publication-author-cunningham-eb","publication-author-dore-gj","publication-author-estes-c","publication-author-gray-rt","publication-author-grebely-j","publication-author-guy-r","publication-author-hajarizadeh-b","publication-author-hcv-estimates-and-projections-reference-group","publication-author-kwon-ja","publication-author-power-c","publication-author-razavi-h"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=2401"}],"version-history":[{"count":10,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2401\/revisions"}],"predecessor-version":[{"id":7503,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2401\/revisions\/7503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3193"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=2401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=2401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=2401"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=2401"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}